Why Is MIRA Pharmaceuticals Stock Gaining Tuesday?
MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones for non-opioid inflammatory pain relief.
Stocks · News reference
MIRA Pharmaceuticals Files Phase 2a Clinical Study Protocol To FDA For Ketamir-2 Oral NMDA Receptor Modulator
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MIRA Pharmaceuticals shares are trading higher after the company announced results from the completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs.
MIRA Pharmaceuticals Says 7-Day Dose-Range Finding Toxicology Studies Of MIRA-55 In Rats And Dogs Completed, Supporting Next Phase Of IND-Enabling Program; Targets IND Submission In Q1 2027
8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)
Filed: 2026-09-01 AccNo: 0001493152-26-040930 Size: 238 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits